Biomaterial Database

Relationship between 15-hydroxyprostaglandin dehydrogenase and gastric adenocarcinoma. 2014

Jae Hyun Kang, and Sang Hyun Kang, and Sang Hyuk Seo, and Jae Ho Shin, and Min Sung An, and Tae Kwun Ha, and Ki Beom Bae, and Tae Hyun Kim, and Chang Soo Choi, and Sang Hoon Oh, and Mi Seon Kang, and Kwang Hee Kim

Department of Surgery, Inje University College of Medicine, Busan, Korea.

OBJECTIVE Prostaglandin E2 (PGE2) is a contributory carcinogen in gastric adenocarcinoma. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) catabolizes PGE2 by oxidizing its 15(s)-hydroxy group. The aim of this study was to investigate the expression of 15-PGDH in gastric adenocarcinoma tissue and the relationship between 15-PGDH expression and clinicopathologic features of gastric adenocarcinoma. METHODS Ninety-nine patients who underwent surgical resection for gastric adenocarcinoma between January 2007 and December 2007 were enrolled and evaluated retrospectively. RESULTS In 62 patients (62.6%), 15-PGDH expression was lower in gastric adenocarcinoma tissue than in nonneoplastic tissue. Regarding the relationship between 15-PGDH expression and clinicopathological features, 15-PGDH expression was significantly lower in tissues with poor differentiation (P = 0.002), advanced T stage (P = 0.0319), a higher number of lymph node metastases (P = 0.045), lymphatic invasion (P = 0.031), and vascular invasion (P = 0.036). CONCLUSIONS 15-PGDH expression was associated with a subset of clinicopathologic features such as differentiation grade, T stage, lymphatic invasion, and vascular invasion.